252 related articles for article (PubMed ID: 24138307)
21. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou M; Kastritis E; Ntanasis-Stathopoulos I; Fotiou D; Roussou M; Migkou M; Ziogas DC; Kanellias N; Terpos E; Dimopoulos MA
Blood; 2018 Jan; 131(4):464-467. PubMed ID: 29167176
[No Abstract] [Full Text] [Related]
22. Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Cabrera César E; Fernández Aguirre MC; González Fernández A
Arch Bronconeumol; 2017 Jun; 53(6):355-356. PubMed ID: 27939513
[No Abstract] [Full Text] [Related]
23. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Tannemaat MR; Vries EP; Molendijk WJ; Haan J
Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
[No Abstract] [Full Text] [Related]
24. Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Meunier M; Larabi A; Schacherer M; Deteix C; Courby S; Cahn JY
Ann Hematol; 2020 Feb; 99(2):379-380. PubMed ID: 31822948
[No Abstract] [Full Text] [Related]
25. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Anderson KC; Prince HM
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
[No Abstract] [Full Text] [Related]
26. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
[No Abstract] [Full Text] [Related]
27. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Jena RK; Swain TR; Kansurkar SS; Swain M
Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
[TBL] [Abstract][Full Text] [Related]
28. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
[No Abstract] [Full Text] [Related]
29. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
[No Abstract] [Full Text] [Related]
30. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
[TBL] [Abstract][Full Text] [Related]
31. [The use of lenalidomide in the treatment of multiple myeloma].
Holánek M; Hájek R
Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
[TBL] [Abstract][Full Text] [Related]
33. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
36. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
37. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
38. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Musolino C; Alonci A; Catena S; Rizzotti P; Russo S; Rotondo F; Allegra A
Acta Oncol; 2013 Jun; 52(5):1050-1. PubMed ID: 23113590
[No Abstract] [Full Text] [Related]
39. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Monaghan SA; Dai L; Mapara MY; Normolle DP; Gollin SM; Lentzsch S
Leuk Lymphoma; 2013 Sep; 54(9):1965-74. PubMed ID: 23216269
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Michot C; Guillot B; Dereure O
Dermatology; 2010; 220(1):49-50. PubMed ID: 19907136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
